WuXi Biologics wins ABL Bio contract for bispecific antibodies

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Ruskpp)
(Image: Getty/Ruskpp)

Related tags: CDMO, Wuxi biologics, South korea, China

South Korean biotech ABL Bio has selected WuXi Biologics to develop and manufacture up to eight bispecific antibodies for the clinic.

ABL Bio Corporation’s bispecific antibodies, which bind two different epitopes either on the same or different targets, are being developed for immune-oncology and neurodegenerative diseases.

WuXi Biologics and ABL Bio’s agreement will see the Chinese contract development and manufacturing organisation (CDMO) prepare up to eight bispecific antibodies for clinical trials.

Candidates will be selected from both ABL Bio’s pipeline and collaboration programmes​ between ABL Bio and I-Mab Biopharma.

“The partnership with WuXi Biologics is an important strategy for growing our internal and external programmes of next-generation…biologics, such as [the] bispecific antibody,” ​said ABL Bio CEO Sang Hoon Lee in a statement.

For WuXi Biologics, the exclusive partnership marks its first in South Korea. The CDMO is expanding internationally, with an estimated capacity of 220,000 litres planned across China, Ireland​, Singapore​, and the US​ by 2021.

Earlier this month, the firm broke ground​ on its eight drug substance manufacturing facility – located in China’s Hebei province – and announced plans​ to build a discovery, development and manufacturing site in the Fengxian district of Shanghai.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars